Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) witnessed a selling pressure and the shares last traded with a loss of -0.92 points or -0.8% at $113.99. Investors jumped in to buy the shares on weakness. The net money flow till latest update was calculated at $2.86 million with an inflow of $7.78 million in upticks and an outflow of $4.91 million in downticks. Using the data, the up/down ratio is found to be 1.58. The share price has recorded 1.42% on a weekly basis.A block trade of $2.38 million in uptick and $0 million in downtick was also observed, resulting in an up/down ratio of 0. The net money flow of the block trade stood at a $2.38, signaling heavy buying.
The stock has recorded a 20-day Moving Average of 2.9% and the 50-Day Moving Average is 5.07%. The company shares have rallied 15.48% in the past 52 Weeks. On April 22, 2016 The shares registered one year high of $131.84 and one year low was seen on August 24, 2015 at $71.63. The 50-day moving average is $118.1 and the 200 day moving average is recorded at $107.94. S&P 500 has rallied 1.93% during the last 52-weeks.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): The stock opened at $115.02 on Tuesday but the bulls could not build on the opening and the stock topped out at $115.04 for the day. The stock traded down to $112.89 during the day, due to lack of any buying support eventually closed down at $113.99 with a loss of -0.80% for the day. The stock had closed at $114.91 on the previous day. The total traded volume was 231,500 shares.
Currently the company Insiders own 14.7% of Ligand Pharmaceuticals Incorporated shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -13.24% . During last six month period, the net percent change held by insiders has seen a change of -6.47%. On the companys insider trading activities,The director of Ligand Pharmaceuticals Inc, Kozarich John W sold 1,000 shares at $118.33 on June 1, 2016. The Insider selling transaction had a total value worth of $118,330. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them with a lean corporate cost structure. The Companys technology CAPTISOL is a formulation technology that has enabled seven United States Food and Drug Administration (FDA) approved products including Kyprolis and Noxafil-IV and is being developed in several clinical-stage partner programs. The Company is engaged in the development of product candidates indicated for the treatment of diseases, such as hepatitis, multiple myeloma, muscle wasting, Alzheimers disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis (FSGS) and osteoporosis.